Collectively, candidates from Destiny Pharma’s novel XF platform have demonstrated activity against a range of highly prevalent bacteria responsible for causing serious and multi-drug resistant healthcare acquired infections. These include the most virulent and difficult to target, with eight so far tested that appear on the World Health Organisation and US Centers for Disease Control and Prevention (CDC)’s list of priority pathogens including MRSA (methicillin-resistant Staphylococcus aureus).
